Traders should monitor for topline FURVENT Phase 3 data in mid-2026, which could be a key catalyst. While the growing loss is a concern, the extended cash runway and regulatory progress in China support continued development without near-term dilution risk.
Price Chart
Executive Summary
ArriVent BioPharma reported its 2025 financial results, highlighting clinical progress with its lead asset firmonertinib, including completion of enrollment in the pivotal FURVENT Phase 3 trial for EGFR exon 20 insertion NSCLC and dosing in the ALPACCA Phase 3 trial for PACC mutant NSCLC. The company reported a net loss of $166.3 million in 2025, up from $80.5 million in 2024, with cash and investments totaling $312.8 million as of year-end, sufficient to fund operations into 3Q 2027.
Key Financial Metrics
Key Facts
- Completed enrollment in the global pivotal Phase 3 FURVENT trial for firmonertinib in first-line EGFR exon 20 insertion NSCLC; topline data expected mid-2026.
- Dosed first patient in the global pivotal Phase 3 ALPACCA trial for firmonertinib in first-line PACC mutant NSCLC.
- Partner Shanghai Allist received NMPA approval in China for firmonertinib in second-line EGFR exon 20 insertion NSCLC in February 2026.
- Cash and investments totaled $312.8 million as of December 31, 2025, funding operations into 3Q 2027.
- Net loss increased to $166.3 million in 2025 from $80.5 million in 2024, driven by higher R&D and G&A expenses.
Financial Impact
Net loss nearly doubled year-over-year to $166.3 million; R&D expenses increased 94% to $153.4 million. Cash runway extended to 3Q 2027 despite higher burn.
Risk Factors
- Clinical trial delays or negative topline data in mid-2026 could significantly impact valuation.
- Increasing operating losses and reliance on future financing or partnerships beyond 3Q 2027.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3250640 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 8-K | $23.64 | awaiting T+5 | — | $14.86 (−37.14%) |
Oct 25, 2026 1d ago | Press Release | $21.00 | awaiting T+5 | — | $14.86 (−29.24%) |
Oct 23, 2026 2d ago | Press Release | $21.00 | awaiting T+5 | — | $14.86 (−29.24%) |
Oct 19, 2026 7d ago | 8-K | $17.94 | awaiting T+5 | — | $14.86 (−17.17%) |
Oct 13, 2026 12d ago | SC 13G | $16.20 $19.12 | ▲ +18.02% | ▲ +17.57% | $14.86 (−8.27%) |
Oct 13, 2026 13d ago | 8-K | $16.09 $18.85 | ▲ +17.15% | ▲ +18.31% | $14.86 (−7.64%) |
Oct 8, 2026 17d ago | SC 13D/A | $16.73 $16.66 | ▲ +0.42% | ▼ −1.55% | $14.86 (+11.18%) |
Oct 6, 2026 20d ago | 8-K | $15.09 $16.09 | ▼ −6.63% | ▼ −6.77% | $14.86 (+1.52%) |
Aug 12, 2026 10w ago | Press Release | $30.00 $29.18 | ▲ +2.73% | ▲ +0.77% | $14.86 (+50.47%) |
Jun 11, 2026 19w ago | Institutional Cluster | $30.54 $31.74 | ▲ +3.93% | ▲ +3.26% | $14.86 (−51.34%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers